HD-OPM Archive
Topics › Inflammation & CRP

2025 ACC statement: inflammation is actionable in CVD, with universal hsCRP screening

Gokhan Can · Oct 09, 2025 · ♥ 15 reactions · 13 comments · original Facebook post
Inflammation & CRPRisk assessment & lab testsGuidelines, policy & public health
AI summary & key facts

Summarises the 2025 ACC Scientific Statement (JACC) concluding the inflammation-ASCVD link is now clinically actionable. It recommends universal hsCRP screening in primary and secondary prevention alongside cholesterol, notes IL-6 and fibrinogen also predict risk, and says CT perivascular fat attenuation is promising but not routine. It contrasts this with a more cautious 2002 CDC/AHA workshop.

Inflammation as a key driver of cardiovascular disease
In a landmark 2025 Scientific Statement from the American College of Cardiology, published in the Journal of the American College of Cardiology (JACC), a panel of experts presents a comprehensive update on the role of inflammation in cardiovascular disease (CVD). The statement argues decisively that the link between chronic, low-grade inflammation and atherosclerotic cardiovascular disease (ASCVD) has moved beyond the exploratory phase and is now a compelling, clinically actionable reality. The authors call for a paradigm shift in clinical practice, advocating for near-universal screening for inflammation and the adoption of targeted anti-inflammatory therapies as a standard component of cardiovascular risk reduction.

The Evolution of Understanding: From Hypothesis to Actionable Science

The statement begins by contextualizing the current moment, contrasting it with a more cautious 2002 workshop by the CDC and American Heart Association. While that earlier meeting identified high-sensitivity C-reactive protein (hsCRP) as a promising biomarker, it stopped short of recommending widespread screening due to insufficient evidence. Over the subsequent two decades, a wealth of basic, clinical, and population science research has solidified the understanding that chronic, silent inflammation is a pivotal driver of atherosclerotic plaque formation, progression, rupture, and subsequent thrombotic events. This new body of evidence, anchored by several large-scale, randomized clinical trials, forms the basis for the statement's assertive "call to action."

The central thesis is that clinicians "will not treat what they do not measure." Therefore, the time has come to integrate the assessment and management of inflammatory risk into routine cardiovascular care alongside traditional risk factors like cholesterol and blood pressure.

Biomarkers and Risk Assessment: The Centrality of hsCRP

The document firmly establishes hsCRP as the primary, standardized, and most clinically useful biomarker for assessing silent vascular inflammation.

Imaging biomarkers, such as the perivascular fat attenuation index derived from CT scans, are noted as promising research tools for identifying localized vascular inflammation but are not yet recommended for routine clinical settings.

Inflammation in Primary Prevention

In individuals without known CVD, elevated hsCRP is an unequivocal predictor of future events. A meta-analysis encompassing over 160,000 individuals showed that a one-standard-deviation increase in hsCRP was associated with a 37% increased risk of coronary heart disease and a 55% increased risk of cardiovascular death. The prevalence of this risk is substantial, affecting up to 50% of adults in the United States who have an hsCRP level of 2 mg/L or higher.

The cornerstone of therapeutic evidence in this setting is the JUPITER trial. This study enrolled individuals with normal LDL cholesterol (<130 mg/dL) but elevated hsCRP (≥2 mg/L). Treatment with rosuvastatin resulted in a remarkable 47% reduction in the primary endpoint of major cardiovascular events. This trial definitively proved that a therapy with anti-inflammatory effects provides significant benefit in a population selected for inflammatory risk, even when cholesterol levels are not elevated.

Secondary Prevention and Residual Inflammatory Risk

For patients with established CVD, the concept of "residual inflammatory risk" is critical. This refers to the persistent high risk of recurrent events in individuals who have elevated hsCRP despite being on statin therapy and having well-controlled LDL cholesterol.

The statement highlights two seminal trials that have validated direct anti-inflammatory therapy:

Broader Implications: Lifestyle, Heart Failure, and Pericarditis

The statement extends the role of inflammation beyond atherosclerosis:

Call to Action: A New Era in Cardiovascular Prevention

The statement concludes with an emphatic call to action. The evidence linking inflammation to ASCVD is now robust enough to demand changes in clinical practice. The writing committee urges that clinical practice guidelines be updated to:

By endorsing inflammation biology, clinicians can also reinforce the importance of lifestyle interventions like diet, exercise, and weight control, all of which lower hsCRP. The era of treating inflammation as a key target in cardiovascular medicine has, according to this statement, officially arrived.

Paper · J Am Coll Cardiol · 2026Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology.The crucial role of inflammation in the pathogenesis and clinical outcomes of cardiovascular disease (CVD) has recently gained increased attention. In particular, residual inflammation, measured with high-sensitivity C-reactive protein (hsCRP) remains strongly predictive of recurrent events, even in statin-treated patients. Similarly, elevated hsCRP in apparently healthy individuals identifies a higher-risk group in…jacc.org

Research cited

#hscrp#cardiovascular#inflammation#cholesterol#prevention#statins#colchicine#cardiovasculardisease
← newer: Oleic acid may supercharge cancer-fighting immune cells; palolder: Admin prefers recent, local epidemiology because food supply →